eptinezumab is in phase iii trials. its maker plans to submit an application with the fda later this year. it is for chronic migraine prevention.
.get latest news & live updates on the go on your pc with
.
.
classifieds
.
letter exposes 22 lab animal deaths at uc berkeley from 2015 to 2017
.